Acumen posts updated corporate presentation with plasma biomarker data from Phase 1 INTERCEPT-AD trial

Acumen Pharmaceuticals, Inc.

Updated corporate presentation posted to investor website on December 4, 2023.
Includes plasma biomarker data from Phase 1 INTERCEPT-AD trial.
Presentation to be used in upcoming investor conferences and communications.

item 7.01 item 9.01

Acumen Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001576885-23-000068

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.